Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

Stopped The study was terminated prematurely because of difficulty with recruiting.

Conditions

• Disinhibition Syndrome

Interventions

• DRUG: AVP-786
• DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.